Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.
about
Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infectionDistinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse modelInterference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors.Clonotypic composition of the CD4+ T cell response to a vectored retroviral antigen is determined by its speed.Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responsesUsing multivalent adenoviral vectors for HIV vaccinationMyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes.Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infectionImproved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypesCodelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection.Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery.Therapeutic live vaccines as a potential anticancer strategy.Prospects for oral replicating adenovirus-vectored vaccines.The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice.Opposing Development of Cytotoxic and Follicular Helper CD4 T Cells Controlled by the TCF-1-Bcl6 Nexus.Modification of one epitope-flanking amino acid allows for the induction of friend retrovirus-specific CD8+ T cells by Adenovirus-based immunization.The effect of fiber truncations on the stability of adenovirus type 5.Virus-Like-Vaccines against HIV.Oncolytic Adenoviruses in Cancer Treatment.Correlates of Follicular Helper Bias in the CD4 T Cell Response to a Retroviral Antigen.
P2860
Q26748624-4DAB1009-E575-4C51-98BF-C5CCF10F4393Q27003380-69BBEFD7-DBBE-45FC-88FE-76522C487FCFQ33613835-4DF217C8-AFF7-482A-8AAB-DCA9188C46A2Q33993393-1E789846-EFC2-41AC-AF24-C2CF44E54B3AQ34428096-C549E29C-4326-4EAB-9C64-105264CCA08DQ34653777-74D56FD5-3A98-4062-9F99-BB45A55D4D6DQ35046630-F5B3BA23-6E8A-4E7A-9FF1-C5DCB1B2F44FQ35070346-3774B397-B207-446E-AA8C-607295460B40Q35353052-C34F2034-C353-4F57-B6B6-4F5C3FA53FF1Q35689651-4E702C88-5BEA-4A48-90C5-2D3551095EE7Q36330007-6EE1EF74-5435-4053-B349-F0169353B507Q36659279-519A4EF5-95A9-427C-A6A3-4F114668D541Q37628079-BC91C07E-D8CE-44BC-A523-EBBAC779CE67Q38011653-A3FC36D5-EEA7-4851-A737-6E50DC64A296Q38109356-CF229CD2-440E-4D62-87E4-BA0709BD75CCQ38206518-15DB27E0-1614-4445-9B06-463405D77B38Q40212928-9778D04F-70C8-4FA9-A469-421C95EC1C9BQ40469638-FA16CB07-3003-4FF1-9212-D040A29E73B8Q41574561-B93DC1B1-4A6E-4D50-BDBD-691B6D7ED0EBQ42209051-5057AD79-AE53-4E8F-B5FF-755B00C4C07AQ50034030-1A9811C9-D3DE-4B6D-93C1-59CE626252E8Q51849210-A0F87252-4D07-4F96-AD1E-A6B1ADCCC137Q55382966-0752CB4C-4433-4756-A7B0-C131E3464256
P2860
Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Vaccination with an adenoviral ...... d confers enhanced protection.
@ast
Vaccination with an adenoviral ...... d confers enhanced protection.
@en
type
label
Vaccination with an adenoviral ...... d confers enhanced protection.
@ast
Vaccination with an adenoviral ...... d confers enhanced protection.
@en
prefLabel
Vaccination with an adenoviral ...... d confers enhanced protection.
@ast
Vaccination with an adenoviral ...... d confers enhanced protection.
@en
P2093
P2860
P50
P356
P1433
P1476
Vaccination with an adenoviral ...... nd confers enhanced protection
@en
P2093
Lena Johrden
Oliver Wildner
Ruth Lietz
Simone Schimmer
P2860
P304
P356
10.1128/JVI.01840-09
P577
2009-12-09T00:00:00Z